Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

Eli Lilly on Wednesday said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 diabetes.

CNBC’s Annika Kim Constantino has the details.